Literature DB >> 26408644

Molecular and cellular mechanisms of glucagon-like peptide-1 receptor agonist-mediated attenuation of cardiac fibrosis.

Tracey Gaspari1, Melita Brdar1, Huey Wen Lee1, Iresha Spizzo1, Yunshan Hu2, Robert E Widdop1, Richard W Simpson2, Anthony E Dear3.   

Abstract

BACKGROUND: Glucagon-like peptide-1 receptor agonists may have a role in modulation of cardiac fibrosis. Our study aimed to determine the effect of the glucagon-like peptide-1 receptor agonist liraglutide in obesity, hypertension and age-induced murine models of cardiac fibrosis and identify associated molecular mechanisms.
METHODS: C57Bl/6J mice on a high-fat diet and C57Bl/6J mice on a normal chow diet treated with angiotensin II were used to induce obesity and hypertension-mediated cardiac fibrosis, respectively. C57Bl/6J mice 20 months old were used to study age-induced cardiac fibrosis. Liraglutide treatment of 30 µg/kg/day-300 µg/kg s.c. twice daily was administered for 4 weeks.
RESULTS: Liraglutide treatment attenuated obesity, hypertension and age-induced increases in interstitial cardiac fibrosis and expression of inflammatory and oxidative stress markers.
CONCLUSIONS: These observations identify a potential role for liraglutide in the prevention of cardiac fibrosis and identify molecular mechanisms associated with these effects.
© The Author(s) 2015.

Entities:  

Keywords:  Glucagon-like peptide-1 receptor agonist; anti-inflammatory; cardiac fibrosis; macrophage; oxidative stress

Mesh:

Substances:

Year:  2015        PMID: 26408644     DOI: 10.1177/1479164115605000

Source DB:  PubMed          Journal:  Diab Vasc Dis Res        ISSN: 1479-1641            Impact factor:   3.291


  7 in total

1.  Ameliorative Impact of Liraglutide on Chronic Intermittent Hypoxia-Induced Atrial Remodeling.

Authors:  Jun Wang; Yongzheng Liu; Changhui Ma; Yue Zhang; Meng Yuan; Guangping Li
Journal:  J Immunol Res       Date:  2022-04-13       Impact factor: 4.493

2.  Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies.

Authors:  Fernanda Cristina de Mesquita; Sergi Guixé-Muntet; Anabel Fernández-Iglesias; Raquel Maeso-Díaz; Sergi Vila; Diana Hide; Martí Ortega-Ribera; José Luís Rosa; Juan Carlos García-Pagán; Jaime Bosch; Jarbas Rodrigues de Oliveira; Jordi Gracia-Sancho
Journal:  Sci Rep       Date:  2017-06-12       Impact factor: 4.379

3.  Renoprotective effects of a dipeptidyl peptidase 4 inhibitor in a mouse model of progressive renal fibrosis.

Authors:  Takahiro Uchida; Takashi Oda; Hidehito Matsubara; Atsushi Watanabe; Hanako Takechi; Naoki Oshima; Yutaka Sakurai; Hiroo Kumagai
Journal:  Ren Fail       Date:  2017-11       Impact factor: 2.606

Review 4.  Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models.

Authors:  Coenraad Withaar; Carolyn S P Lam; Gabriele G Schiattarella; Rudolf A de Boer; Laura M G Meems
Journal:  Eur Heart J       Date:  2021-11-14       Impact factor: 29.983

Review 5.  Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities.

Authors:  Izabela Tuleta; Nikolaos G Frangogiannis
Journal:  Adv Drug Deliv Rev       Date:  2021-07-29       Impact factor: 17.873

6.  Liraglutide attenuates cardiac remodeling and improves heart function after abdominal aortic constriction through blocking angiotensin II type 1 receptor in rats.

Authors:  Rong-Hua Zheng; Xiao-Jie Bai; Wei-Wei Zhang; Jing Wang; Feng Bai; Cai-Ping Yan; Erskine A James; Himangshu S Bose; Ning-Ping Wang; Zhi-Qing Zhao
Journal:  Drug Des Devel Ther       Date:  2019-08-06       Impact factor: 4.162

7.  The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction.

Authors:  Coenraad Withaar; Laura M G Meems; George Markousis-Mavrogenis; Cornelis J Boogerd; Herman H W Silljé; Elisabeth M Schouten; Martin M Dokter; Adriaan A Voors; B Daan Westenbrink; Carolyn S P Lam; Rudolf A de Boer
Journal:  Cardiovasc Res       Date:  2021-07-27       Impact factor: 10.787

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.